A randomized, double-blinded, controlled clinical trial was conducted to assess the efficacy of topical phenytoin compared to conventional wound care in improving the healing process and to prove it as a relatively low-cost and easy-to-use option in the management of diabetic ulcers. Patients over 18 years of age with type 2 diabetes and foot ulcers over 1 month duration were randomized to receive daily dressings containing either powder A (test powder containing topical phenytoin and metronidazole) or powder B (control powder containing topical metronidazole) for 14 days, following which, they underwent split-skin grafting. The percentage of decrease in the ulcer surface area, rate of granulation tissue formation, graft uptake, and percentage of negative culture sensitivity were compared between the two groups using the unpaired Student’s t test. A p value <0.05 was considered significant. Patient demographic and socioeconomic characteristics of the two groups were well matched. The primary outcome measured as the mean rate of decrease of size of the ulcer in patients of group A was 30.69 (±5.50 SD) and in group B was 24.43 (±5.96 SD) percent of total ulcer area (p < 0.0001). The mean rate of increase of granulation tissue in group A was 69 (±10.16 SD) percent of total ulcer area and in group B was 51.51 (±10.54 SD) percent of total ulcer area (p < 0.0001). Out of the 97 patients, 75 underwent grafting. The mean graft take up in group A was 76.57 % (±19.06 SD) and in group B was 66.48 % (±17.67 SD) (p = 0.0082). Forty-three percent of the study group was culture negative at day 14, of which 54.2 % belonged to group A as compared to 45.8 % in group B. Topical phenytoin is an effective, inexpensive, and easily available agent in the promotion of healing of diabetic foot ulcers.
Diabetes Ulcer Healing Phenytoin Surgery
This is a preview of subscription content, log in to check access.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Source of funding
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
Molvær AK, Graue M, Espehaug B, Østbye T, Midthjell K, Iversen MM. Diabetes-related foot ulcers and associated factors: results from the Nord-Trøndelag health survey (HUNT3) (2006-2008). J Diabetes Complicat 2014; 28 : 156–161.CrossRefPubMedGoogle Scholar
Fowler EM, Vesely N, Johnson V, Harwood J, Tran J, Amberry T. Wound care for patients with diabetes. Adv Skin Wound Care. 2003;16:342–6.CrossRefPubMedGoogle Scholar
Nazemisalman B, Vahabi S, Bandehpour M, Aryankia AK. Phenytoin effects on inflammatory mediator's production by gingival fibroblasts: a comparative study in children and adults. Oral Health Dent Manag 2014; 13 : 847–853.PubMedGoogle Scholar
DaCosta ML, Regan MC, al Sader M, Leader M, Bouchier-Hayes D. Diphenylhydantoin sodium promotes early and marked angiogenesis and results in increased collagen deposition and tensile strength in healing wounds. Surgery 1998; 123: 287–293.Google Scholar
Scheinfeld N. Phenytoin in cutaneous medicine: its uses, mechanisms and side effects. Dermatol Online J 2003; 9: 6PubMedGoogle Scholar
Ng LS, Kwang LL, Yeow SC, Tan TY. Anaerobic culture of diabetic foot infections: organisms and antimicrobial susceptibilities. Ann Acad Med Singap 2008; 37 : 936–939.PubMedGoogle Scholar
Shapiro M Acceleration of gingival wound healing in non-epileptic patients receiving diphenylhydantoin sodium (dilantin, epanutin). Exp Med Surg. 1958;16:41–53.PubMedGoogle Scholar
Carneiro PM, Rwanyuma LR, Mkony CA. A comparison of topical phenytoin with silverex in the treatment of superficial dermal burn wounds. Cent Afr J Med 2002; 48 : 105–108.PubMedGoogle Scholar
Subbanna PK, Margaret Shanti FX, George J, Tharion G, Neelakantan N, Durai S, et al. Topical phenytoin solution for treating pressure ulcers: a prospective, randomized, double-blind clinical trial. Spinal Cord 2007;45:739–743.CrossRefPubMedGoogle Scholar
Krieg T, Schurig V, Braun-Falco O. Hereditary bullous epidermolyses. Recent aspects of diagnosis and therapy. Hautarzt 1986;37:185–189.PubMedGoogle Scholar
Ali OM, El-Sayed WA, Eid SA, Abdelwahed NA, Abdel-Rahman AA. Antimicrobial activity of new synthesized [(oxadiazolyl)methyl] phenytoin derivatives. Acta Pol Pharm 2012;69:657–667.PubMedGoogle Scholar
Modaghegh S, Salehian B, Tavassoli M, Djamshidi A, Rezai AS. Use of phenytoin in healing of war and non-war wounds. A pilot study of 25 cases. Int J Dermatol 1989;28:347–350.CrossRefPubMedGoogle Scholar
Black JA, Liu S, Carrithers M, Carrithers LM, Waxman SG. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 2007;62:21–33.CrossRefPubMedGoogle Scholar
Lai ML, Tien YE, Huang YS, Huang JD. Studies on pharmacokinetic mechanism of phenytoin resistance in refractory epilepsy. J Pharm Sci 2013;102:3189–3195.CrossRefPubMedGoogle Scholar
Patil V, Patil R, Kariholu PL, Patil LS, Shahapur P. Topical phenytoin application in grade I and II diabetic foot ulcers: a prospective study. J Clin Diagn Res 2013;7:2238–2240.PubMedPubMedCentralGoogle Scholar
Shaw J, Hughes CM, Lagan KM, Stevenson MR, Irwin CR, Bell PM. The effect of topical phenytoin on healing in diabetic foot ulcers: a randomized controlled trial. Diabet Med 2011;28:1154–1157.CrossRefPubMedGoogle Scholar
El-Nahas M, Gawish H, Tarshoby M, State O. The impact of topical phenytoin on recalcitrant neuropathic diabetic foot ulceration. J Wound Care 2009;18:33–37.CrossRefPubMedGoogle Scholar
Bhatia A, Prakash S. Topical phenytoin for wound healing. Dermatol Online J. 2004;10:5.PubMedGoogle Scholar